Equities

Neuraxis Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Neuraxis Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)5.39
  • Today's Change0.48 / 9.78%
  • Shares traded111.00
  • 1 Year change+123.19%
  • Beta--
Data delayed at least 15 minutes, as of Feb 17 2026 21:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments3.700.080.25
Total Receivables, Net0.240.070.17
Total Inventory0.040.020.05
Prepaid expenses0.280.070.00
Other current assets, total------
Total current assets4.270.240.48
Property, plant & equipment, net0.370.160.19
Goodwill, net------
Intangibles, net0.100.110.08
Long term investments------
Note receivable - long term------
Other long term assets0.02----
Total assets4.760.511.48
LIABILITIES
Accounts payable0.601.201.59
Accrued expenses1.640.450.87
Notes payable/short-term debt000.29
Current portion long-term debt/capital leases0.150.150.20
Other current liabilities, total0.040.084.03
Total current liabilities2.431.896.98
Total long term debt000
Total debt0.150.150.49
Deferred income tax------
Minority interest------
Other liabilities, total0.260.030.08
Total liabilities2.691.917.05
SHAREHOLDERS EQUITY
Common stock0.010.010.00
Additional paid-in capital594728
Retained earnings (accumulated deficit)(57)(49)(34)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity2.07(1.4)(5.57)
Total liabilities & shareholders' equity4.760.511.48
Total common shares outstanding6.996.516.11
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.